Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Inflammatory Breast Neoplasms 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 11Radiotherapy 11Filgrastim 6Granulocyte Colony-Stimulating Factor 4Chemotherapy, Adjuvant 4etoposide phosphate 3Topotecan 3O(6)-benzylguanine 3Melphalan 3Etoposide 3Cyclophosphamide 3Carboplatin 3sodium thiosulfate 2sargramostim 2Thiotepa 2Radiotherapy, Intensity-Modulated 2Methylphenidate 2Mannitol 2Ifosfamide 2Carmustine 2Busulfan 2Bone Marrow Transplantation 2Bevacizumab 2transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1temsirolimus 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1poly ICLC 1pentetreotide 1pemigatinib 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Central Nervous System Neoplasms × bemcentinib × Clear all
NCT03965494 2024-02-08

AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Terminated
10 enrolled
CNS

Glioblastoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡